IPO Trending
ANLSME / BSEListed
Accretion Nutraveda

Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and nutraceutical products across multiple dosage forms such as tablets, capsules, oral liquids, powders, oils, and external applications including balms, creams, and gels, operating as a Contract Development and Manufacturing Organization (CDMO) for both domestic and international markets including Sri Lanka, Singapore, and the USA. The company blends classical Ayurvedic formulations with modern nutraceutical science to address wellness segments such as liver care, women’s health, bone and joint health, cognitive support, and respiratory health, with its revenue primarily driven by domestic sales and merchant exports on a loan license basis, along with a growing contribution from direct exports. It operates a 10,763 sq. ft. manufacturing facility in Gujarat equipped with modern infrastructure, multiple air handling units, segregated processing areas, and quality control systems, and holds certifications including GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, Halal, and FSSAI.

₹122 - ₹1291.91x sub
Listed Price₹191.00
Listing Gain+48.06%

Subscription Status

1.91xTotal Demand
Updated 23 Sept 2026, 02:50 PM
QIB1.01x
Fully Subscribed (Safe)Offered: 3,64,000 sh
Nib2.42x
Fully Subscribed (Safe)Offered: 2,76,000 sh
Hnis(10l +)2.47x
Fully Subscribed (Safe)Offered: 1,84,000 sh
Hnis (2-10l)2.33x
Fully Subscribed (Safe)Offered: 92,000 sh
Retail2.19x
Fully Subscribed (Safe)Offered: 6,40,000 sh
CategoryOfferedAppliedTimes
QIB3,64,0003,67,0001.01x
Nib2,76,0006,69,0002.42x
Hnis(10l +)1,84,0004,55,0002.47x
Hnis (2-10l)92,0002,14,0002.33x
Retail6,40,00014,04,0002.19x

Segment Subscription Demand

Segment / CategoryDemand (Shares)Offered (Shares)Times Sub.
QIB4.734.71.01x
Fiis4.670Open
Others0.060Open
Retail18.118.262.19x
Hnis 2+2.761.192.32x
Hnis 10+5.872.372.48x

Application-wise Breakup

CategoryReservedAppliedTimes Sub.
QIB02Open
Nib0107Open
Retail3207022.19x
Hnis(10l +)61450.74x
Hnis (2-10l)31622.00x
Bidding status cross-verified with live IPO subscription numbers ↗BSE & NSE Bidding Portal Feed

About Accretion Nutraveda IPO Subscription Demand

Live subscription status and bidding analysis for Accretion Nutraveda (ANL) IPO. The issue is subscribed 1.91x overall across Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII/HNI), and Retail Individual Investors (RII). Check real-time grey market demand on our GMP Tracker or review full issue details, lot size, and price band on the IPO Details Page.

Frequently Asked Questions